Building the Future of Camino Science, Together
Your foundational AI platform has the potential to redefine biotech. This interactive proposal outlines a collaborative, data-driven partnership to transform Camino Science from a brilliant technology into a venture-backed, market-defining enterprise.
Challenge & Opportunity
Camino Science is at a critical inflection point. To attract premier investors in today's "flight to quality" market, we must address key milestones together.
Focus the Platform
Identify and validate the single most compelling market application to demonstrate clear product-market fit, a prerequisite for funding in a cautious market.
Complete the Team
Overcome the solo-founder hurdle. Data shows teams secure 83% of VC funding versus only 17% for individuals. This partnership immediately creates the balanced team investors want.
Prepare for Investment
Navigate the financial cleanup, address existing debt, and optimize the cap table to present a clean, professional, and de-risked opportunity to sophisticated institutional investors.
Our Joint Blueprint for Value Creation
A three-pillar action plan to systematically de-risk the company and unlock its full potential.
Pillar 1: Fundable Business Model
Lead a rigorous discovery process to identify the most compelling application for the AI model, creating a data-driven business plan that transforms the technology into an investable company.
Pillar 2: Secure Seed Funding
Spearhead a professional fundraising effort to secure a €5M-€10M seed round at a premium valuation from top-tier VCs, creating a competitive process to ensure the best terms.
Pillar 3: Build Leadership Team
Once funded, lead the executive search to recruit a permanent, world-class biotech CEO to ensure long-term success and allow the founder to focus on technical innovation.
Interactive Value Creation Model
The goal is not to divide the current pie, but to grow a much larger one. This model demonstrates how strategic partnership creates exponential value for all stakeholders.
Long-Term Value Projections
Select a scenario to see how the value of each stake grows through successive funding rounds.
(Note: Projections assume the Employee Stock Option Pool is topped up to 8% at each funding round.)
| Stage | Investment | Valuation | Founder Ownership Value | Angel Ownership Value | MBA 1 Ownership Value | MBA 2 Ownership Value | Employee Stock Option Pool | Investors Ownership Value |
|---|
Stakeholder Value Growth Over Time
A Fair and Aligned Partnership Structure
The proposed terms are designed to be transparent, founder-friendly, and grounded in market data to ensure a win-win structure.
We propose an equity stake of
11.5% each
(23% combined), earned as a success fee for creating over €17M in new enterprise value.
Market-Calibrated Justification
Pre-Seed Biotech
25%
Mean equity for one active, part-time founding scientist (Cornell University). This is comparable to our role in founding the business side of the company, for two people.
Venture Builder
34%
Venture Builders execute the 0-to-1 business creation process. With two founders, this role is often considered equivalent to a third founder, where equity is often equally split 33.3% between all three. The venture builder model's average equity is 34%.
Co-Founder Standard
22%
3-founder splits have a median of 44% (lead), 33% (2nd), and 22% (3rd), per Carta 2025. This is the median equity for a third co-founder.
Institutional Standard
20%
Imperial's 20% benchmark is for therapeutic spinouts receiving extensive support. Our proposal adds a modest 1.5% each to reflect our active, hands-on co-founding role, which goes beyond a support role.
Equity Distribution Comparison
According to Carta, median 3-founder equity splits are 44% (lead), 33% (second), and 22% (third). A traditional second and third co-founder would require a combined 55% equity. Our 23% joint proposal is far more favorable, creating a complete technical and business founding team for a successful fundraise. This equity-efficient approach allows the company to use its seed funding to hire a permanent C-suite when the company is de-risked and talent is far less dilutive (~5% post-seed vs. 33%+ for a pre-seed founding CEO).
Summary of Proposed Terms
Equity Stake
11.5% common shares each (23% combined), dilutable.
Vesting
100% milestone-based, ensuring equity is earned only on delivery of tangible results.
Success Fee
€100K cash bonus per MBA on seed close at €18M+ valuation, paid from proceeds.
Founder Control
Key decisions require 75% shareholder consent, protecting your strategic influence.
No-Risk Trial
A 30-day 'out clause' with no obligations to validate our partnership dynamic.